Alpha Cognition Inc
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael E. McFadden
- Full Time Employees
- 71
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1452 Hughes Street Grapevine TX United States of America 76051
- IPO Date
- Nov 12, 2024
- CIK
- 0001655923
- Website
- alphacognition.com
- Similar Companies
- Business
- Alpha Cognition Inc. (Nasdaq: ACOG) is a commercial-stage biopharmaceutical company that develops and commercializes treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI), primarily in the United States and Canada. The company offers ZUNVEYL (benzgalantamine), an FDA-approved oral tablet prodrug of galantamine indicated for mild-to-moderate Alzheimer's disease that features improved gastrointestinal tolerability and reduced side effects such as nausea; its development pipeline includes ZUNVEYL in combination with memantine for moderate-to-severe Alzheimer's disease, ALPHA-1062 sublingual and intranasal formulations targeting acute pancreatitis and mTBI, respectively, and preclinical assets ALPHA-0602 (progranulin), ALPHA-0702, and ALPHA-0802 for neurodegenerative conditions including amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy, some of which are available for out-licensing. Founded in 2000 and headquartered at 750 West Pender Street, Suite 1200, Vancouver, British Columbia V6C 2T8, Canada, Alpha Cognition targets long-term care facilities, neurology clinics, and institutional pharmacies serving patients with limited treatment options in these high-unmet-need areas. Recent developments include the commercial launch of ZUNVEYL in March 2025 generating approximately $2.8 million in revenue through the second quarter of commercialization; a $44 million exclusive licensing agreement in January 2025 with China Medical System Holdings for ZUNVEYL development and commercialization in China, with the partner's New Drug Application accepted by Chinese regulators in July 2025; a $35 million oversubscribed public offering priced in September 2025; appointment of Robert Wills to the board of directors in April 2025; positive preclinical data announced in July 2025 for ALPHA-1062 in a military-relevant model of repetitive mTBI; FDA approval of ZUNVEYL in July 2024 following New Drug Application submission in September 2023; expansions of commercial, medical, and leadership teams in early 2025 to support launch activities; and a notice of allowance for a composition-of-matter patent for ZUNVEYL in October 2024.
Company News
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Announces CONVERGE Real-World Evidence on ZUNVEYL®(Benzgalantamine) Use in Long-Term Care
Reviewing Alpha Cognition (NASDAQ:ACOG) & Karyopharm Therapeutics (NASDAQ:KPTI)
Analysts Set Alpha Cognition Inc. (NASDAQ:ACOG) Target Price at $18.00
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Alpha Cognition Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) 2Q26
Alpha Cognition Inc. (ACOG) Q2 2026 Earnings Call Transcript
Alpha Cognition Inc. (ACOG) Reports Q2 Loss, Tops Revenue Estimates
Alpha Cognition Q2 Earnings Call Highlights
Alpha Cognition Inc. Reports Second Quarter 2026 Financial Results and Provides Operational Update
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Alpha Cognition to Report Second Quarter 2026 Financial Results and Provide Business Update
Alpha Cognition Receives European Patent Covering ZUNVEYL® for the Treatment of Mild-to-Moderate Alzheimer's Disease
Alpha Cognition Inc. (ACOG) Surges 8.6%: Is This an Indication of Further Gains?
Playing The Biotech Breakout With Insiders
Alpha Cognition to Participate in Panel Discussion at the B. Riley Securities Mind, Muscle & Vision Summit
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board
Alpha Cognition Announces First Patient Enrolled in RESOLVE Phase 4 Study Evaluating ZUNVEYL® in Patients with Mild to Moderate Alzheimer's Disease